BRIEF-Aveo Oncology Posts Q1 Loss Per Share Of $0.81 Reuters 5/10/2021 AVEO ONCOLOGY REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Q1 LOSS PER SHARE $0.81 Q1 REVENUE $1.9 MILLION Q1 EARNINGS PER SHARE ESTIMATE $-0.55 REFINITIV IBES DATA AVEO ONCOLOGY - BELIEVE CASH, EQUIVALENTS, WITH PRODUCT REVENUE FROM FOTIVDA LAUNCH, WOULD ENABLE MAINTANING OPERATIONS FOR AT LEAST 12 MONTHS FROM 10Q FILING AVEO ONCOLOGY - EXPECTS COMMERCIAL SPEND WILL BE APPROXIMATELY $40 MILLION FOR YEAR Source text for Eikon: Further company coverage:
Bristol-Myers Squibb Company (NYSE:BMY), AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) - Aveo Pharma s Tivozanib To Be Tested In Combination With Opdivo In Kidney Cancer
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) - Aveo Pharmaceuticals Stock Volatile After FDA Approval: Technical Levels To Watch
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.